E
Petros Pharmaceuticals, Inc. PTPI
$0.3065 -$0.0135-4.22%
Recommendation
Sell
Prev Close
$0.32
Volume
64,387
Avg Vol (90D)
1,425,990
Market Cap
$3.20M
Dividend & Yield
--
52-Week Range
$0.2208 - $2.27
P/E (TTM)
--
EPS (TTM)
-$4.69
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly ...
1/7/2025 - GuruFocus
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
1/7/2025 - Accesswire
Petros Pharmaceuticals Featured in "New Era of Healthcare, AI, Data and Consumer Empowerment"
12/19/2024 - Accesswire
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
12/17/2024 - Accesswire
Petros Pharmaceuticals (NASDAQ: PTPI) Holds 2024 Annual Meeting of Stockholders
11/23/2024 - Ticker Report
It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year
11/13/2024 - Simply Wall St
Head-To-Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) versus Protagonist Therapeutics (NASDAQ:PTGX)
10/30/2024 - Ticker Report
Petros Pharmaceuticals Amends President's Employment Terms
10/18/2024 - TipRanks Financial Blog
Board Reshuffle at Petros Pharmaceuticals Following Resignations
10/4/2024 - TipRanks Financial Blog
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Sees Large Drop in Short Interest
9/28/2024 - Zolmax
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Update
9/27/2024 - Ticker Report
Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%
9/25/2024 - Ticker Report
Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra
9/12/2024 - TipRanks Financial Blog
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
9/11/2024 - Accesswire
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
9/3/2024 - Accesswire
Petros Pharmaceuticals price target lowered by $3 at Maxim, here's why
8/19/2024 - The Fly
Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)
8/17/2024 - TipRanks Financial Blog
PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
8/17/2024 - InvestorPlace
Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 10.4%
8/6/2024 - Ticker Report
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
7/16/2024 - Accesswire
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
6/17/2024 - Benzinga
Head to Head Analysis: Petros Pharmaceuticals (NASDAQ:PTPI) and COMPASS Pathways (NASDAQ:CMPS)
6/10/2024 - Ticker Report
Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion
5/30/2024 - TipRanks Financial Blog
Petros Pharmaceuticals completes human factors study of AI-integrated web app
5/29/2024 - The Fly
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
5/29/2024 - Accesswire
Income Statement
Total Revenue (TTM)
$4.02M
EBITDA (TTM)
-$10.61M
EBIT (TTM)
-$13.59M
Net Income (TTM)
-$4.73M
Balance Sheet
Total Assets (Q)
$20.69M
Total Debt (Q)
$7.34M
Total Liabilities (Q)
$17.58M
Book Value Per Share (Q)
$0.3111
Cash Flow
Cash from Operations (TTM)
-$5.83M
Cash from Investing (TTM)
-$19.10K
Cash from Financing (TTM)
-$8.23M
Net Change in Cash (TTM)
-$14.08M
Filings
Filing Date
Wednesday, November 13, 2024
Period Date
Monday, September 30, 2024
Next Filing
Beginning of April (est)
Price History
Loading...
Beta
3.18
7-Day Total Return
-18.51%
30-Day Total Return
-8.37%
60-Day Total Return
-8.45%
90-Day Total Return
-12.20%
Year to Date Total Return
-34.44%
1-Year Total Return
-76.24%
2-Year Total Return
-88.17%
3-Year Total Return
-98.16%
5-Year Total Return
--
52-week Low
Nov 15, 2024 - $0.2208
52-week High
Feb 14, 2024 - $2.27
Valuation
Market Cap
$3.20M - Nano Cap
Enterprise Value
$6.65M
Price/Sales (TTM)
0.78
Price/Book (Q)
1.03
Dividends and Shares
Shares Outstanding
9.83M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.petrospharma.com
Phone Number
973 242 0005
Address
1185 Avenue of the Americas
New York, NY 10036
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications... more
NASDAQ 01/22/2025 10:09AM Eastern Quotes delayed
Weiss Ratings